1.30 (-1.32%)
As of Oct 10, 2023
Source:
Zynerba Pharmaceuticals, Inc is the leader in pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, or FXS, and chromosome 22q11.2 deletion syndrome, or 22q.
Country | United States |
Headquarters | devon, pennsylvania |
Phone Number | 484-581-7505 |
Industry | manufacturing |
CEO | Armando Anido |
Website | zynerba.com |